Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

Bio-Path Stock Performance

Shares of Bio-Path stock opened at $0.18 on Monday. Bio-Path has a 1 year low of $0.12 and a 1 year high of $7.67. The business has a 50-day moving average of $0.68 and a two-hundred day moving average of $0.85.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.